A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Novavax Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 44,260 shares of NVAX stock, worth $381,521. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,260
Previous 141,775 68.78%
Holding current value
$381,521
Previous $1.79 Million 68.84%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$10.71 - $17.11 $1.04 Million - $1.67 Million
-97,515 Reduced 68.78%
44,260 $559,000
Q2 2024

Aug 09, 2024

BUY
$3.89 - $20.97 $551,504 - $2.97 Million
141,775 New
141,775 $1.79 Million
Q2 2022

Aug 05, 2022

SELL
$36.28 - $75.29 $9.41 Million - $19.5 Million
-259,383 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$69.73 - $142.9 $5.29 Million - $10.8 Million
75,823 Added 41.31%
259,383 $19.1 Million
Q4 2021

Feb 10, 2022

SELL
$134.56 - $217.97 $162,279 - $262,871
-1,206 Reduced 0.65%
183,560 $26.3 Million
Q3 2021

Nov 12, 2021

BUY
$177.8 - $270.58 $20.8 Million - $31.7 Million
117,238 Added 173.61%
184,766 $38.3 Million
Q2 2021

Aug 12, 2021

BUY
$121.0 - $257.67 $3.86 Million - $8.23 Million
31,931 Added 89.7%
67,528 $14.3 Million
Q1 2021

May 13, 2021

SELL
$112.98 - $319.93 $2.99 Million - $8.48 Million
-26,493 Reduced 42.67%
35,597 $6.45 Million
Q4 2020

Feb 16, 2021

SELL
$78.74 - $139.5 $311,180 - $551,304
-3,952 Reduced 5.98%
62,090 $6.92 Million
Q3 2020

Nov 12, 2020

BUY
$79.44 - $178.51 $1.71 Million - $3.84 Million
21,498 Added 48.26%
66,042 $7.16 Million
Q2 2020

Aug 13, 2020

BUY
$13.86 - $83.61 $617,379 - $3.72 Million
44,544 New
44,544 $3.71 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $674M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.